FDA wants more research before considering Pfizer RA drug Xeljanz for use in psoriasis
On October 14, 2015, Pfizer announced that the US Food and Drug Administration (FDA) has declined to approve Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib citrate) to treat moderate to severe plaque psoriasis in adult patients.
The FDA, in what is called a Complete Response Letter, made recommendations to Pfizer about what additional information it should provide to try again to win approval of Xeljanz for psoriasis.